McKesson (MCK) stock is in focus after a cluster of recent moves, including a US$2.25b senior secured term loan maturing in 2032, a minority sale in Medical-Surgical Solutions and ongoing share repurchases.

After a weaker quarter and a pullback that left the 90 day share price return down 14.66% and the year to date share price return down 4.62%, McKesson still has a 1 year total shareholder return of 8.87% and a very large 5 year total shareholder return. This suggests that long term holders have been rewarded even as recent momentum has cooled and investors reassess the impact of the new term loan, portfolio moves and insider activity.

If McKesson's recent financing and portfolio reshaping has you thinking about where capital is flowing next, it may be worth scanning for opportunities in healthcare focused artificial intelligence stocks using the 40 healthcare AI stocks.

With McKesson stock pulling back after a softer quarter but still carrying a long term track record and active buybacks, is this a rare discount or is the market already pricing in everything ahead?

Most Popular Narrative: 17.3% Undervalued

Compared with McKesson's last close at $785.43, the most followed narrative points to a fair value of $949.73, anchoring a clear valuation gap for investors to weigh.

Expanding value added services, such as pharmacy management, patient access/adherence solutions, and commercialization support for biopharma customers, allow for stronger customer relationships, greater recurring revenue streams, and improved revenue visibility. Increasing complexity of the pharmaceutical supply chain (e.g., biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top line and margin expansion.

Want to see what sits behind that valuation gap? The narrative leans on steady top line expansion, stable margins, and a future earnings multiple that assumes McKesson keeps compounding its scale advantages.

Result: Fair Value of $949.73 (UNDERVALUED)

However, the McKesson narrative can be challenged if tighter drug price regulation squeezes already thin margins, or if vertically integrated payers and PBMs reduce reliance on wholesalers.

Another View: McKesson Stock Through the P/E Lens

While the leading McKesson narrative leans on a fair value of $949.73, the current P/E of 19.3x versus the US Healthcare industry at 23.2x, peers at 23.9x and a fair ratio of 27.3x points to a clear discount that could reflect either opportunity or embedded risk.

To see how firmly the current price lines up against these earnings multiples, sense check those gaps against your own expectations for margins, growth and capital allocation using the See what the numbers say about this price — find out in our valuation breakdown..

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out McKesson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seen enough to sense both optimism and caution around McKesson? With risks and rewards pulling in different directions, it helps to weigh the detail yourself with the 4 key rewards and 1 important warning sign.

Looking for more ideas beyond McKesson stock?

If McKesson has your attention, do not stop there. Use the Simply Wall Street Screener to spot other potential opportunities before they move without you.

• Target potential mispricings by running through 44 high quality undervalued stocks, so you can quickly see which companies align with your return expectations.
• Strengthen your income stream by scanning 9 dividend fortresses and focus on companies where yield and stability go hand in hand.
• Reduce downside surprises by filtering for 67 resilient stocks with low risk scores, giving you a starting list of stocks with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.